Firefly Neuroscience (NASDAQ:AIFF) Posts Quarterly Earnings Results

Firefly Neuroscience (NASDAQ:AIFF) posted its quarterly earnings results on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, Zacks reports. Firefly Neuroscience had a negative net margin of 2,705.88% and a negative return on equity of 319.00%. The company had revenue of $0.41 million during the quarter.

Firefly Neuroscience Price Performance

Shares of AIFF stock traded down $0.01 during trading on Wednesday, hitting $2.17. 1,526,525 shares of the stock traded hands, compared to its average volume of 10,152,879. Firefly Neuroscience has a 52-week low of $0.62 and a 52-week high of $4.51. The firm has a market capitalization of $30.87 million, a P/E ratio of -1.06 and a beta of 1.92. The firm’s fifty day moving average price is $1.28 and its 200-day moving average price is $1.66.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Firefly Neuroscience in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in shares of Firefly Neuroscience during the fourth quarter worth about $53,000. Geode Capital Management LLC increased its holdings in Firefly Neuroscience by 92.9% in the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after buying an additional 58,067 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after buying an additional 401,085 shares during the last quarter. 4.96% of the stock is owned by institutional investors and hedge funds.

About Firefly Neuroscience

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.